Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 90

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 90
---
 to domestic U.S. issuers; •For as long as we remain an emerging growth company, or EGC, we will be exempt from certain securities laws requirements, including the fact that our auditors are not required to conduct an audit of our internal control over financial reporting; however, once we cease to qualify as an EGC, we will no longer be permitted to rely on such exemptions and as a result we will incur additional legal, accounting and other expenses; and •We have identified material weaknesses in our internal control over financial reporting and instituted ongoing remediation efforts. If our ongoing remediation efforts are not effective, we may not be able to accurately or timely report our financial results, or prevent fraud, and investor confidence in our Company and the market price of our common shares and Warrants may be adversely affected. 19 See the section entitled “ Where You Can Find More Information” beginning on page 241 of this proxy statement/prospectus for more information about the SEC filings incorporated by reference into this proxy statement/prospectus. Nasdaq Capital Market Listing (see page 125) Prior to consummation of the Merger, NLS intends to file a listing of additional securities application with Nasdaq, as required by Nasdaq to effect the issuance of NLS Common Shares in connection with the Merger or upon exercise of options or warrants or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares that will be assumed by NLS in connection with the Merger. If such application is accepted, NLS anticipates that its securities will be listed on the Nasdaq Capital Market following the Closing, and subject to approval of Proposals1,2,4,6,8, 12 and 13 in the NLS Meeting, will trade under NLS’s new name, NUCLEX AG. Anticipated Accounting Treatment (Pages 125) The most recent financial information available for NLS for the six months ended June 30, 2024, and twelve months ended December 31, 2023, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The most recent financial information available for Kadimastem for the six months ended June 30, 2024, and twelve months ended December 31, 2023, have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Boards. The Merger is anticipated to be accounted